The promise of bispecific antibodies: Clinical applications and challenges

Sun Min Lim; Kyoung Ho Pyo; Ross A. Soo; Byoung Chul Cho

doi:10.1016/j.ctrv.2021.102240

The promise of bispecific antibodies: Clinical applications and challenges

Sun Min Lim, Kyoung Ho Pyo, Ross A. Soo, Byoung Chul Cho

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

23 Citations (Scopus)

Abstract

The development of cancer therapies using monoclonal antibodies has been successful during the last 30 years. Recently much progress was achieved with technologies involving bispecific and multi-specific antibodies. Bispecific antibodies (BsAbs) are antibodies that bind two distinct epitopes, and a large number of potential clinical applications of BsAbs have been described. Here we review mechanism of action, clinical development and future challenges of BsAbs which could be a serve as a valuable arsenal in cancer patients.

Original language	English
Article number	102240
Journal	Cancer Treatment Reviews
Volume	99
DOIs	https://doi.org/10.1016/j.ctrv.2021.102240
Publication status	Published - 2021 Sept

Bibliographical note

Publisher Copyright:
© 2021 Elsevier Ltd

All Science Journal Classification (ASJC) codes

Oncology
Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ctrv.2021.102240

Cite this

@article{27b4ca467b654cc9b041220ca2a96bdd,

title = "The promise of bispecific antibodies: Clinical applications and challenges",

abstract = "The development of cancer therapies using monoclonal antibodies has been successful during the last 30 years. Recently much progress was achieved with technologies involving bispecific and multi-specific antibodies. Bispecific antibodies (BsAbs) are antibodies that bind two distinct epitopes, and a large number of potential clinical applications of BsAbs have been described. Here we review mechanism of action, clinical development and future challenges of BsAbs which could be a serve as a valuable arsenal in cancer patients.",

author = "Lim, {Sun Min} and Pyo, {Kyoung Ho} and Soo, {Ross A.} and Cho, {Byoung Chul}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = sep,

doi = "10.1016/j.ctrv.2021.102240",

language = "English",

volume = "99",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - The promise of bispecific antibodies

T2 - Clinical applications and challenges

AU - Lim, Sun Min

AU - Pyo, Kyoung Ho

AU - Soo, Ross A.

AU - Cho, Byoung Chul

PY - 2021/9

Y1 - 2021/9

N2 - The development of cancer therapies using monoclonal antibodies has been successful during the last 30 years. Recently much progress was achieved with technologies involving bispecific and multi-specific antibodies. Bispecific antibodies (BsAbs) are antibodies that bind two distinct epitopes, and a large number of potential clinical applications of BsAbs have been described. Here we review mechanism of action, clinical development and future challenges of BsAbs which could be a serve as a valuable arsenal in cancer patients.

AB - The development of cancer therapies using monoclonal antibodies has been successful during the last 30 years. Recently much progress was achieved with technologies involving bispecific and multi-specific antibodies. Bispecific antibodies (BsAbs) are antibodies that bind two distinct epitopes, and a large number of potential clinical applications of BsAbs have been described. Here we review mechanism of action, clinical development and future challenges of BsAbs which could be a serve as a valuable arsenal in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85107647059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107647059&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2021.102240

DO - 10.1016/j.ctrv.2021.102240

M3 - Review article

C2 - 34119803

AN - SCOPUS:85107647059

SN - 0305-7372

VL - 99

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

M1 - 102240

ER -

The promise of bispecific antibodies: Clinical applications and challenges

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this